Bicycle Therapeutics Reveals Promising Imaging Data at AACR

Bicycle Therapeutics ( (BCYC) ) has issued an update.

On April 29, 2025, Bicycle Therapeutics announced additional human radiopharmaceutical imaging data for MT1-MMP at the AACR Annual Meeting 2025, demonstrating the potential of MT1-MMP as a novel cancer target. The data, involving 12 patients with various solid tumors, highlighted the efficacy of Bicycle® Radioconjugates (BRC®) in radiopharmaceutical imaging, showing promising results in tumor targeting and tracer uptake. The company plans to advance its radiopharmaceutical pipeline with initial human imaging data for a second target, EphA2, expected later in 2025, and company-sponsored clinical trials planned for 2026.

Spark’s Take on BCYC Stock

According to Spark, TipRanks’ AI Analyst, BCYC is a Neutral.

Bicycle Therapeutics is currently facing significant challenges with operational losses and negative cash flow, which weigh heavily on its financial performance. Although the company is experiencing revenue growth, this has not yet translated into profitability. The technical analysis suggests a bearish trend, and the valuation is unattractive due to negative earnings. Despite these hurdles, the company’s strong balance sheet provides some financial stability, offering a foundation to support potential future improvements in operational efficiency.

To see Spark’s full report on BCYC stock, click here.

More about Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company focused on developing a novel class of medicines called Bicycle® molecules, which are synthetic short peptides designed for high affinity and selectivity in target binding. The company is exploring treatments for diseases underserved by existing therapeutics, including oncology, and is headquartered in Cambridge, UK, with key operations in Cambridge, Massachusetts.

YTD Price Performance: -41.50%

Average Trading Volume: 357,405

Technical Sentiment Signal: Buy

Current Market Cap: $580.1M

For an in-depth examination of BCYC stock, go to TipRanks’ Stock Analysis page.